T2D.com Review
Best for: diabetic GLP-1 access
T2D.com offers a complete service for compounded semaglutide and tirzepatide that includes the prescriber, medication, and home delivery in one integrated solution. A subsidiary of Vertical Insight Corp, the program is built specifically for individuals managing type 2 diabetes and pre-diabetes.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
T2D.com is a solid telehealth option with balanced features and pricing.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Starting dose | compounded | $999 |
| Starting dose | compounded | $999 |
✓ Pros
- •Built specifically for type 2 diabetic and pre-diabetic patients
- •Integrated service — prescriber, pharmacy, and delivery handled in one flow
- •Offers both compounded semaglutide and compounded tirzepatide
- •Temperature-controlled home delivery via UPS or FedEx
- •Ongoing prescriber monitoring and support included
✗ Cons
- •No pricing published on the public website — must register to see costs
- •No states list published on the site
- •Newer brand with limited independent reviews
- •Compounded only — no brand-name Ozempic, Wegovy, or Mounjaro
Ready to start with T2D.com?
Starting at $999/month. See current pricing and start your free consultation.
Sources & methodology
Our T2D.com review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to T2D.com
Alan Meds
Best for: budget-conscious shoppers
AmberHealth
Best for: budget-conscious shoppers
Amble
Best for: mainstream telehealth GLP-1 access
Frequently Asked Questions
Ready to start with T2D.com?
Starting at $999/month. See current pricing and start your free consultation.